RE:Sortina Pharma - more signs Sort1 as marker for brain cancer "In conclusion, the present study points to sortilin as a new potential clinical biomarker for predicting GBM aggressiveness and patient survival. In addition, targeting sortilin seems to decrease GBM cell invasion, and could therefore be used in GBM therapy. Although further in vivo studies are needed, it should be noted that sortilin targeting in human cancers has recently entered a clinical trial phase. In breast [30], thyroid [37] and ovarian cancer [38], targeting sortilin has been shown to enhance the effect of existing chemotherapy by exploiting sortilin function as a receptor allowing targeted entry of a peptide conjugated to docetaxel (TH1902) [10,38,39,40]. There is currently a clinical trial underway targeting sortilin in patients with advanced solid tumors using TH1902 (NCT04706962). This phase 1 clinical trial will include patients with solid tumors in the breast, ovary, endometrium, skin, thyroid, lung, and prostate, and our findings suggest that GBM should be added to the list of cancers that could incorporate sortilin targeting as a therapeutic option."
Funny enough I sent this to the CMO few weeks ago the issue is BBB, I looked into that to and there are some suggestions, such as i interventricular administration etc.
Wino115 wrote: The Swedish group, pursuing the stem cell disruptive approach to stopping cancers overexpressing sort1, has extended their research to show it's also a useful biomarker and possibly a therapeutic target for a form of brain cancer. Always a bit trickier cancer. Their pre-clinical research followed a similar tissue sample study as THTX and other reseachers have done over the last few years showing sort1 overexpression and how it progresses with the stage of the cancer. More highlighting of the target as highly prospective for therapies is a positive.
https://pubmed.ncbi.nlm.nih.gov/37173980/